Andrew Tsai
Stock Analyst at Jefferies
(4.82)
# 523
Out of 4,444 analysts
156
Total ratings
59.1%
Success rate
27.4%
Average return
Main Sectors:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRAX Praxis Precision Medicines | Maintained: Buy | $525 → $550 | $308.94 | +78.03% | 7 | Jun 23, 2026 | |
| DFTX Definium Therapeutics | Rated: Buy | $35 | $42.13 | -16.92% | 4 | Jun 22, 2026 | |
| MRNA Moderna | Maintained: Hold | $45 | $60.42 | -25.52% | 7 | Jun 16, 2026 | |
| CMPS COMPASS Pathways | Maintained: Buy | $18 | $12.58 | +43.08% | 2 | May 14, 2026 | |
| ANRO Alto Neuroscience | Maintained: Buy | $35 | $24.91 | +40.51% | 8 | May 14, 2026 | |
| AXSM Axsome Therapeutics | Maintained: Buy | $200 | $237.92 | -15.94% | 2 | May 1, 2026 | |
| DRUG Bright Minds Biosciences | Initiated Coverage: Buy | $145 | $66.22 | +118.97% | 1 | Apr 12, 2026 | |
| BBIO BridgeBio Pharma | Maintained: Buy | $100 | $69.36 | +44.18% | 9 | Mar 31, 2026 | |
| BIIB Biogen | Maintained: Buy | $210 | $199.59 | +5.22% | 6 | Mar 12, 2026 | |
| XENE Xenon Pharmaceuticals | Rated: Buy | $65 → $100 | $55.58 | +79.92% | 24 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $4.17 | +139.81% | 11 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $22 | $5.09 | +332.22% | 1 | Feb 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 → $30 | $16.70 | +79.69% | 12 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $7.5 | $5.90 | +27.12% | 1 | Dec 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $15 → $0.9 | $0.6648 | +35.38% | 5 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $3 → $5 | $4.33 | +15.47% | 2 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $30 | $30.39 | -1.28% | 2 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $32 | $30.65 | +4.40% | 1 | Nov 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $5.30 | +88.68% | 7 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $2.5 → $3 | $3.30 | -9.09% | 5 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $3 → $0.85 | $2.22 | -61.71% | 2 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8.5 | $5.83 | n/a | 7 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $45.14 | n/a | 9 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $35 | $40.00 | n/a | 3 | Dec 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $3 → $0.5 | $8.59 | n/a | 9 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $75 → $13 | $6.51 | n/a | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $42 | $20.33 | n/a | 5 | Jun 24, 2024 |
Praxis Precision Medicines
Jun 23, 2026
Maintained: Buy
Price Target: $525 → $550
Current: $308.94
Upside: +78.03%
Definium Therapeutics
Jun 22, 2026
Rated: Buy
Price Target: $35
Current: $42.13
Upside: -16.92%
Moderna
Jun 16, 2026
Maintained: Hold
Price Target: $45
Current: $60.42
Upside: -25.52%
COMPASS Pathways
May 14, 2026
Maintained: Buy
Price Target: $18
Current: $12.58
Upside: +43.08%
Alto Neuroscience
May 14, 2026
Maintained: Buy
Price Target: $35
Current: $24.91
Upside: +40.51%
Axsome Therapeutics
May 1, 2026
Maintained: Buy
Price Target: $200
Current: $237.92
Upside: -15.94%
Bright Minds Biosciences
Apr 12, 2026
Initiated Coverage: Buy
Price Target: $145
Current: $66.22
Upside: +118.97%
BridgeBio Pharma
Mar 31, 2026
Maintained: Buy
Price Target: $100
Current: $69.36
Upside: +44.18%
Biogen
Mar 12, 2026
Maintained: Buy
Price Target: $210
Current: $199.59
Upside: +5.22%
Xenon Pharmaceuticals
Mar 9, 2026
Rated: Buy
Price Target: $65 → $100
Current: $55.58
Upside: +79.92%
Mar 9, 2026
Maintained: Buy
Price Target: $10
Current: $4.17
Upside: +139.81%
Feb 1, 2026
Initiated Coverage: Buy
Price Target: $22
Current: $5.09
Upside: +332.22%
Jan 12, 2026
Maintained: Buy
Price Target: $35 → $30
Current: $16.70
Upside: +79.69%
Dec 31, 2025
Maintained: Hold
Price Target: $7.5
Current: $5.90
Upside: +27.12%
Dec 17, 2025
Downgraded: Hold
Price Target: $15 → $0.9
Current: $0.6648
Upside: +35.38%
Dec 1, 2025
Maintained: Hold
Price Target: $3 → $5
Current: $4.33
Upside: +15.47%
Nov 24, 2025
Maintained: Buy
Price Target: $30
Current: $30.39
Upside: -1.28%
Nov 21, 2025
Initiated Coverage: Buy
Price Target: $32
Current: $30.65
Upside: +4.40%
Nov 11, 2025
Maintained: Buy
Price Target: $10
Current: $5.30
Upside: +88.68%
Aug 8, 2025
Maintained: Hold
Price Target: $2.5 → $3
Current: $3.30
Upside: -9.09%
Aug 6, 2025
Maintained: Hold
Price Target: $3 → $0.85
Current: $2.22
Upside: -61.71%
Mar 26, 2025
Maintained: Buy
Price Target: $8.5
Current: $5.83
Upside: n/a
Mar 12, 2025
Reiterated: Buy
Price Target: $40
Current: $45.14
Upside: n/a
Dec 7, 2024
Rated: Buy
Price Target: $35
Current: $40.00
Upside: n/a
Sep 18, 2024
Rated: Hold
Price Target: $3 → $0.5
Current: $8.59
Upside: n/a
Sep 16, 2024
Upgraded: Buy
Price Target: $75 → $13
Current: $6.51
Upside: n/a
Jun 24, 2024
Maintained: Buy
Price Target: $42
Current: $20.33
Upside: n/a